

Odayme Quesada,<sup>a</sup>  
Brittney Gurda,<sup>a</sup> Lakshmanan  
Govindasamy,<sup>a</sup> Robert  
McKenna,<sup>a</sup> Erik Kohlbrenner,<sup>b</sup>  
George Aslanidi,<sup>b</sup>  
Sergei Zolotukhin,<sup>b</sup> Nicholas  
Muzyczka<sup>c</sup> and Mavis Agbandje-  
McKenna<sup>a\*</sup>

<sup>a</sup>Department of Biochemistry and Molecular Biology, McKnight Brain Institute, Center for Structural Biology, University of Florida, Gainesville, FL 32610, USA, <sup>b</sup>Division of Cell and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA, and <sup>c</sup>Department of Molecular Genetics and Microbiology and Powell Gene Therapy Center, College of Medicine, University of Florida, Gainesville, FL 32610, USA

Correspondence e-mail: mckenna@ufl.edu

Received 19 October 2007

Accepted 17 November 2007

## Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7

Crystals of baculovirus-expressed adeno-associated virus serotype 7 capsids diffract X-rays to  $\sim 3.0$  Å resolution. The crystals belong to the rhombohedral space group  $R\bar{3}$ , with unit-cell parameters  $a = 252.4$ ,  $c = 591.2$  Å in the hexagonal setting. The diffraction data were processed and reduced to an overall completeness of 79.0% and an  $R_{\text{merge}}$  of 12.0%. There are three viral capsids in the unit cell. The icosahedral threefold axis is coincident with the crystallographic threefold axis, resulting in one third of a capsid (20 monomers) per crystallographic asymmetric unit. The orientation of the viral capsid has been determined by rotation-function searches and is positioned at (0, 0, 0) by packing considerations.

### 1. Introduction


Adeno-associated viruses (AAVs) are nonpathogenic ssDNA viruses that belong to the *Dependovirus* genus of the *Parvoviridae* and are under development for corrective human gene-delivery applications (Muzyczka & Berns, 2001). AAV7 was the first novel AAV sequence isolated from rhesus monkey heart (Gao *et al.*, 2002). The AAV serotypes demonstrate differences in cell tropism and transgene expression in specific tissues (Gao *et al.*, 2004). For example, the efficiency of skeletal muscle transduction with the nonhuman primate AAV7 and AAV8 viruses is significantly greater than that observed with the human AAV2 and AAV5 viruses (Louboutin *et al.*, 2005). In addition, gene-delivery vectors based on nonhuman primate AAVs such as AAV7 have low reactivity to antibodies directed against human AAVs and are thus considered to be promising vehicles for human gene-therapy applications (Gao *et al.*, 2006).

AAV capsids are composed of a total of 60 copies of three overlapping capsid viral proteins (VPs), VP1, VP2 and VP3, in a predicted ratio of 1:1:10, arranged with  $T = 1$  icosahedral symmetry. In the crystal structures of AAV2, AAV4 and AAV8 only the common VP3 region of the VPs is observed (Govindasamy *et al.*, 2006; Nam *et al.*, 2007; Xie *et al.*, 2002). A small number of variable amino acids in the overlapping VP3 dictate the recognition of different cell-surface glycans and therefore the differential tropism and transduction properties of the AAVs (Gao *et al.*, 2004; Kern *et al.*, 2003; Opie *et al.*, 2003; Wu *et al.*, 2006). In addition, comparison of the AAV2, AAV4 and AAV8 structures showed that regions controlling AAV2 receptor recognition, transduction and antigenic reactivity are commonly varied in the other serotypes (Nam *et al.*, 2007). Thus, understanding the AAV capsid structures and their interactions with cellular factors is a prerequisite for their modification for cell/tissue-specific targeted applications. We report the production, purification, crystallization and preliminary crystallographic analysis of AAV7 capsids as a first step towards structural studies to identify the regions of this virus responsible for its capsid-associated enhanced muscle transduction phenotype.

### 2. Materials and methods

#### 2.1. Production and purification

A recombinant baculovirus encoding the AAV7 viral capsid open reading frame (ORF) was constructed using the Bac-to-Bac system



(Gibco BRL). DH10Bac-competent cells containing the baculovirus genome were transformed with pFastBac transfer plasmids containing the AAV7 component insert. Bacmid DNA purified from recombination-positive white colonies was transfected into Sf9 cells using TransIT Insecta reagent (Mirus). 3 d post-transfection, media containing baculovirus (pooled viral stock) were harvested and a plaque assay was used to prepare independent plaque isolates. Several individual plaques were propagated to passage one (P1) to assay for expression of the AAV7 capsid genes and a selected clone was propagated to P2. A titered P2 stock was used to infect Sf9 insect cells grown in Erlenmeyer flasks at 300 K using Sf-900 II SFM media (Gibco/Invitrogen Corporation). The cells were infected at a multiplicity of infection of 5.0 plaque-forming units per cell for viral capsid production.

The virus capsids were released from the cells by three rapid freeze–thaw cycles in lysis buffer (50 mM Tris–HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.2% Triton X-100) with the addition of benzonase (Merck KGaA, Germany) in the final cycle. The sample was clarified by two rounds of centrifugation at 10 000 rev min<sup>-1</sup> for 15 min at 277 K. The cell lysate was pelleted through a 20% (w/v) sucrose cushion by ultracentrifugation at 45 000 rev min<sup>-1</sup> for 3 h at 277 K. The pellet from the cushion was resuspended in lysis buffer by repeated pipetting and left overnight at 277 K for further suspension. The resuspended sample was subjected to a low-speed 2000 rev min<sup>-1</sup> spin to remove particulate material and further purified with two rounds of sucrose-step gradients [5–40% (w/v)] by ultracentrifugation at 35 000 rev min<sup>-1</sup> for 3 h at 277 K. A visible blue fraction containing empty (no DNA) viral capsids sedimenting at the 20–25% sucrose fractions was extracted after the second gradient and dialyzed against 20 mM Tris–HCl pH 7.5 containing 350 mM NaCl and 2 mM MgCl<sub>2</sub> by stirring overnight at 277 K. The approximate concentration of the sample was calculated from optical density measurements assuming an extinction coefficient of 1.7 for calculations in mg ml<sup>-1</sup>. The concentration was adjusted to ~10 mg ml<sup>-1</sup> using Centricon filters (Amicon Centricons, 100 000 molecular-weight cutoff) at 3000 rev min<sup>-1</sup> at 277 K. The purity and integrity of the viral capsids were checked by SDS–PAGE and negative-stain electron microscopy, respectively.

## 2.2. Electron microscopy

Purified AAV7 viral capsids were viewed using a Joel JEM-100CX II electron microscope (EM). 5 µl purified virus solution at an estimated concentration of 2.0 mg ml<sup>-1</sup> was spotted onto a 400 mesh carbon-coated copper grid (Ted Pella, Inc., Redding, California, USA) for 2 min before blotting with filter paper (Whatman No. 5). The sample was then negatively stained with 5 µl 2% uranyl acetate for 17 s, blotted dry and viewed.

## 2.3. Crystallization

Based on reports for the AAV1 (Miller *et al.*, 2006), AAV4 (Kaludov *et al.*, 2003), AAV5 (DiMattia *et al.*, 2005) and AAV8 (Lane *et al.*, 2005) viral capsids, AAV7 crystallization conditions were screened against precipitant solutions containing varying polyethylene glycol (PEG) 8000 percentages (4–6%), NaCl (350 mM–1 M) and MgCl<sub>2</sub> (10–20 mM) concentrations and pH range (pH 6.0–8.0) at room temperature (RT) and 277 K. A buffer concentration of 20 mM for both bis-Tris (pH 6.0 and 6.5) and Tris–HCl (pH 7.0–8.5) was used for the pH screens. The crystal screens were set up using the hanging-drop vapour-diffusion method (McPherson, 1982) with 24-well VDX plates and siliconized cover slips (Hampton Research, Laguna Niguel, California, USA). The crystallization drops contained


2 µl sample solution (at ~10 mg ml<sup>-1</sup>) and 2 µl precipitant solution and were equilibrated against 1 ml precipitant solution.

## 2.4. Data collection and reduction

X-ray diffraction data were collected from AAV7 crystals at 100 K at the 22-ID SER-CAT beamline (Advanced Photon Source, Argonne). A crystal-to-detector distance of 400 mm was used with an oscillation angle of 0.3° per image. A total of 271 images were collected from crystals diffracting X-rays to ~3.0 Å resolution using a wavelength of 0.9724 Å. All the images were indexed, integrated and scaled with the *HKL-2000* package (Otwinowski & Minor, 1997).

## 2.5. Molecular replacement: particle orientation and position determination

The orientation of the AAV7 viral capsid in the crystal unit cell was calculated using the *GLRF* self-rotation function program (Tong & Rossmann, 1997) with observed data between 10.0 and 6.0 Å resolution. The positions of the viral capsid fivefold, threefold and twofold icosahedral symmetry axes were searched with  $\kappa = 72, 120$  and  $180^\circ$ , respectively. The calculations used ~10% of the largest amplitudes to represent the second Patterson and a radius of integration of 130 Å. Based on the self-rotation results, a cross-rotation search was conducted with the *AMoRe* program (Navaza, 1994) using 20 AAV4 VP subunits (PDB code 2g8g; Govindasamy *et al.*, 2006) with residues modified to alanines (a polyalanine model). Structure factors were calculated for the AAV4 model using the *SFALL* subroutine in *CCP4* (Collaborative Computational Project, Number 4, 1994). The AAV4 polyalanine model was oriented into the AAV7 crystal unit cell based on the cross-rotation search results and positioned at (0, 0, 0) based on crystal symmetry constraints to generate initial phases for the observed AAV7 structure factors. Noncrystallographic symmetry (NCS) operators were generated using the 20 AAV4 VP subunit model for further refinement of the AAV7 structure by alternative cycles of phase refinement, density averaging and model building (Brünger *et al.*, 1998; Emsley & Cowtan, 2004; Jones *et al.*, 1991).



**Figure 1** Purification and crystallization of AAV7 viral capsids. (a) SDS–PAGE gel showing the AAV7 viral proteins VP2 and VP3 (molecular weights 73 and 62 kDa, respectively) assembled into capsids in the baculovirus expression system in the right lane. VP1 was not present in the capsids. The left lane shows the position of molecular-weight standards (kDa). (b) Transmission electron micrograph of intact AAV7 capsids stained with 2% uranyl acetate. (c) Optical photograph of an AAV7 capsid crystal.

**Table 1**

Crystal data-collection and processing statistics for AAV7 crystal.

Values in parentheses are for the highest resolution shell.

Space group	<i>R</i> 3 (hexagonal setting)
Unit-cell parameters (Å)	<i>a</i> = 252.4, <i>c</i> = 591.2
<i>V<sub>M</sub></i> (Å <sup>3</sup> Da <sup>-1</sup> )	3.2
Total reflections	468474
Unique reflections	221627 (13633)
Crystal mosaicity (°)	0.55
Resolution range (Å)	50–3.0 (3.11–3.0)
Completeness (%)	79.0 (48.5)
<i>R<sub>merge</sub></i> † (%)	12.0 (48.7)
Redundancy	2.1
Average <i>I</i> /σ( <i>I</i> )	8.2

† *R<sub>merge</sub>* is defined as  $\sum_{hkl} \sum_i |I_i(hkl) - \overline{I(hkl)}| / \sum_{hkl} \sum_i I_i(hkl) \times 100$ , where *I<sub>i</sub>*(*hkl*) is the intensity of an individual reflection and  $\overline{I(hkl)}$  is the average intensity for this reflection; the summation is over all intensities.

### 3. Results and discussion

#### 3.1. Crystallization

The purity and integrity of the AAV7 capsids were confirmed with SDS–PAGE (Fig. 1*a*) and negative-stain EM (Fig. 1*b*) prior to crystallization. The SDS–PAGE analysis showed that the baculovirus-expressed capsids contained VP2 and VP3 but no detectable levels of the AAV7 VP1, as had been reported for other expressed AAV capsids (Kohlbrenner *et al.*, 2005). However, this low expression was not detrimental to the assembly of the capsids (Fig. 1*b*), as also previously reported (Kohlbrenner *et al.*, 2005). Negative-stain EM analysis showed the expressed capsids to be intact. AAV7 crystals grew at RT from conditions consisting of varying NaCl concentrations (350 mM to 1 M NaCl) and 20 mM MgCl<sub>2</sub> in 20 mM Tris–HCl pH 7.0 with 5% PEG 8000. The crystals used for X-ray diffraction data collection were selected from 20 mM Tris pH 7.0, 350 mM NaCl, 20 mM MgCl<sub>2</sub> and 5% PEG 8000. These crystals were obtained in approximately three weeks and grew to dimensions of ~0.2 × 0.1 ×


0.1 mm (Fig. 1*c*). The crystals were cryoprotected with 30% glycerol in the crystallization solution adjusted to 10% PEG 8000 and flash-cooled prior to data collection.

#### 3.2. X-ray data collection and reduction


The crystals diffracted to ~3.0 Å resolution using synchrotron X-rays (Fig. 2). The crystals belong to the rhombohedral crystal system in space group *R*3, with unit-cell parameters *a* = 245.1 Å,  $\alpha$  = 62°. The unit cell was converted into the hexagonal setting (*a* = 252.4, *c* = 591.2 Å) for further calculations. The data set is 79.0% complete, contains 221 627 unique reflections and scaled with an overall *R<sub>merge</sub>* of 12.0%. An average mosaicity of 0.55° was observed during data scaling. The data-processing and scaling statistics are summarized in Table 1. The Matthews coefficient (*V<sub>M</sub>*; Matthews, 1968) was calculated to be 3.2 Å<sup>3</sup> Da<sup>-1</sup> assuming a solvent content of ~60.0% with 20 copies of the AAV7 VP3 monomer present in the crystallographic asymmetric unit as suggested by volume calculations and space-group considerations.

#### 3.3. Molecular replacement: determination of particle orientation and position

The self-rotation function search identified the orientation of the twofold, threefold and fivefold icosahedral symmetry elements for the AAV7 viral capsid within the *R*3 unit cell (Fig. 3). Space-group packing constraints place the AAV7 capsid at the origin (0, 0, 0) of the unit cell with an icosahedral threefold axis along the *c* axis of the hexagonal setting cell (Fig. 3). Thus, the crystallographic asymmetric unit contains one third of the 60 monomer subunits (20 VPs) in the *T* = 1 icosahedral capsid. 20 polyalanine VP subunits of AAV4 were used for the calculation of initial phases for the molecular-replacement structure determination of the AAV7 capsid based on cross-rotation search results in the *AMoRe* program (Navaza, 1994)


**Figure 2**

X-ray diffraction image of an AAV7 crystal: image of a typical 0.3° oscillation photograph. The inner and outer concentric rings indicate the 5.0 and 3.2 Å resolution shells, respectively.


**Figure 3**

AAV7 viral capsid orientation in the *H*3 hexagonal crystal unit-cell setting. The red and blue contours show the fivefold and threefold icosahedral symmetry elements, respectively, for self-rotation function searches with  $\kappa = 72^\circ$  and  $120^\circ$ . The contours are at  $2\sigma$  intervals. The peaks representing fivefold positions are delineated by the black pentagon.

and space-group packing considerations. The  $R$  factor and correlation coefficient were 45.4% and 66.5%, respectively, for this initial molecular-replacement procedure.

This solution was refined with cycles of simulated annealing, individual  $B$ -factor refinement and energy-minimization procedures applying NCS operators in the *CNS* program (Brünger *et al.*, 1998) interspersed with rounds of manual model building using the program *Coot* (Emsley & Cowtan, 2004), but the  $R_{\text{work}}$  and  $R_{\text{free}}$  values did not converge to less than 38.6% and 39.3%, respectively. These results therefore called for a re-examination of the X-ray diffraction data with the possibility of partial twinning (Yeates, 1997). The data were therefore tested for hemihedral twinning using the twinning software in *CNS* and were shown to have a slight twinning fraction of 0.133 when applying the twinning operator  $h, -h - k, -l$ .

The previous structure solution (which had converged to an  $R_{\text{work}}$  of 38.6% without taking into account that the data were twinned) was then further refined within the *CNS* software package using the twinning fraction and the twinning operator. The current  $R$  factor is 29.4%. Once refined, the AAV7 X-ray structure will be compared with those available for other AAV serotypes, for example, AAV2 (Xie *et al.*, 2002), AAV4 (Govindasamy *et al.*, 2006) and AAV8 (Nam *et al.*, 2007), for further characterization of AAV capsid regions responsible for their differential tissue tropism and transduction efficiencies. Ultimately, structure information on the AAV serotypes will provide a three-dimensional platform for mutagenesis efforts to improve specific cell/tissue-targeting gene-delivery applications for these viral vectors.

The authors would like to thank the staff at the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source (APS), Argonne National Laboratory. We thank Hyun-Joo Nam for help with X-ray diffraction data collection. Use of APS is supported by the US Department of Energy, Basic Energy Sciences, Office of Science under contract No. W-31-109-ENG-38. This study was funded by NIH project R01 GM082946 to RM, NM, SZ and MA-M.

## References

Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* **D54**, 905–921.

Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.

DiMattia, M., Govindasamy, L., Levy, H. C., Gurda-Whitaker, B., Kalina, A., Kohlbrenner, E., Chiorini, J. A., McKenna, R., Muzyczka, N., Zolotukhin, S. & Agbandje-McKenna, M. (2005). *Acta Cryst.* **F61**, 917–921.

Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.

Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J. & Wilson, J. M. (2002). *Proc. Natl Acad. Sci. USA*, **99**, 11854–11859.

Gao, G., Lu, Y., Calcedo, R., Grant, R. L., Bell, P., Wang, L., Figueredo, J., Lock, M. & Wilson, J. M. (2006). *Mol. Ther.* **13**, 77–87.

Gao, G. P., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X. & Wilson, J. M. (2004). *J. Virol.* **78**, 6381–6388.

Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A. & Agbandje-McKenna, M. (2006). *J. Virol.* **80**, 11556–11570.

Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991). *Acta Cryst.* **A47**, 110–119.

Kaludov, N., Padron, E., Govindasamy, L., McKenna, R., Chiorini, J. A. & Agbandje-McKenna, M. (2003). *Virology*, **306**, 1–6.

Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A. & Kleinschmidt, J. A. (2003). *J. Virol.* **77**, 11072–11081.

Kohlbrenner, E., Aslanidi, G., Nash, K., Shklyayev, S., Campbell-Thompson, M., Byrne, B. J., Snyder, R. O., Muzyczka, N., Warrington, K. & Zolotukhin, S. (2005). *Mol. Ther.* **12**, 1217–1225.

Lane, M. D., Nam, H.-J., Padron, E., Gurda-Whitaker, B., Kohlbrenner, E., Aslanidi, G., Byrne, B., McKenna, R., Muzyczka, N., Zolotukhin, S. & Agbandje-McKenna, M. (2005). *Acta Cryst.* **F61**, 558–561.

Louboutin, J. P., Wang, L. & Wilson, J. M. (2005). *J. Gene Med.* **4**, 442–451.

McPherson, A. (1982). *Preparation and Analysis of Protein Crystals*, 1st ed., pp. 96–99. New York: Wiley.

Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.

Miller, E. B., Gurda-Whitaker, B., Govindasamy, L., McKenna, R., Zolotukhin, S., Muzyczka, N. & Agbandje-McKenna, M. (2006). *Acta Cryst.* **F62**, 1271–1274.

Muzyczka, N. & Berns, K. I. (2001). *Fields Virology*, 4th ed., edited by D. M. Knipe & P. M. Howley, pp. 2327–2360. New York: Lippincott, Williams & Wilkins.

Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S. & Agbandje-McKenna, M. (2007). *J. Virol.* **81**, 12260–12712.

Navaza, J. (1994). *Acta Cryst.* **A50**, 157–163.

Opie, S. R., Warrington, K. H. Jr, Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. (2003). *J. Virol.* **77**, 6995–7006.

Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.

Tong, L. & Rossmann, M. G. (1997). *Methods Enzymol.* **276**, 594–611.

Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M. & Samulski, R. J. (2006). *J. Virol.* **80**, 11393–11397.

Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A. & Chapman, M. S. (2002). *Proc. Natl Acad. Sci. USA*, **99**, 10405–10410.

Yeates, T. O. (1997). *Methods Enzymol.* **276**, 345–358.